title: Phase I study of subcutaneous allergen immunotherapy with Dermatophagoides pteronyssinus in patients with allergic rhinoconjunctivitis with or without asthma.
abstract: OBJECTIVE
  A double-blind placebo-controlled study was conducted according to EMA guidelines, to evaluate safety, tolerability and short-term treatment effects of three updosing regimens of Dermatophagoides pteronyssinus subcutaneous allergen immunotherapy.
  
  
  METHODS
  Forty-eight patients were randomized to groups: A (six weekly doses), B (eight weekly doses) or C (eight doses, two clustered doses over 3 weeks).
  
  
  RESULTS
  The most frequent adverse events were local reactions. No serious adverse events were found. Severe systemic reactions were reported more frequently in Group C. Decreased cutaneous responses and increased specific IgGs were shown in all active groups, even within the short-term.
  
  
  CONCLUSIONS
  Dermatophagoides pteronyssinus subcutaneous allergen immunotherapy in depot presentation exhibited good safety and tolerability. Group A seemed to show the best profile for further clinical development.
authors: Allergy Department, IIS Hospital La Fe, Valencia, Spain.
authors: Dolores
authors: D
authors: Hernández Fernández de Rojas
authors: Ignacio
authors: I
authors: Antépara Ercoreca
authors: Ana
authors: A
authors: Ponte Tellechea
authors: Ethel
authors: E
authors: Ibáñez Echevarría
authors: Ignacio
authors: I
authors: Jáuregui Presa
authors: Pedro
authors: P
authors: Gamboa Setién
authors: Juan A
authors: JA
authors: Asturias
authors: Araitz
authors: A
authors: Landeta Manzano
authors: Begoña
authors: B
authors: Madariaga Goirigolzarri
mesh_terms: D000328:Adult; D000818:Animals; D039741:Antigens, Dermatophagoides / Q000008:administration & dosage* / Q000276:immunology; D003233:Conjunctivitis, Allergic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D040002:Dermatophagoides pteronyssinus; D003888:Desensitization, Immunologic; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D007279:Injections, Subcutaneous; D008297:Male; D065631:Rhinitis, Allergic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
chemical_list: D039741:Antigens, Dermatophagoides; D007074:Immunoglobulin G
keywords: Dermatophagoides pteronyssinus; allergen; house dust mites; rhinoconjunctivitis; safety; subcutaneous allergen immunotherapy; tolerability